December 03, 2024FinancialNotice Concerning Status of Acquisition of Own Shares (PDF 88.66 KB) (Acquisition of the Company's own shares under articles of incorporation pursuant to the paragraph 2 of Article 165 of the Companies Act of Japan)
December 03, 2024CorporateMulti-Center Superiority Clinical Trial, Supported by Terumo Blood and Cell Technologies, Aims to Significantly Reduce Complications From Acute Chest Syndrome in Adult Sickle Cell Disease Patients
December 03, 2024CorporateTerumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support CatheterProvides interventionalists with optimal product choices for more complex radial-to-peripheral procedures
Top Management Message Message from top management to shareholders and investors. /investors/management/message Corporate Governance /about/governance Compliance /about/compliance Leadership Team /about/leadership Business Risks Major risks that may affect the business performance and financial position of the Terumo Group are described. /investors/management/risk IR Policy /investors/management/ir_policy Disclaimer /investors/disclaimer
